286 related articles for article (PubMed ID: 35237397)
1. Mantle cell lymphoma management trends and novel agents: where are we going?
Pu JJ; Savani M; Huang N; Epner EM
Ther Adv Hematol; 2022; 13():20406207221080743. PubMed ID: 35237397
[TBL] [Abstract][Full Text] [Related]
2. Mantle cell lymphoma and its management: where are we now?
Ladha A; Zhao J; Epner EM; Pu JJ
Exp Hematol Oncol; 2019; 8():2. PubMed ID: 30733891
[TBL] [Abstract][Full Text] [Related]
3. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
[TBL] [Abstract][Full Text] [Related]
4. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
5. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions.
Bond DA; Martin P; Maddocks KJ
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33799484
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapies in mantle cell lymphoma.
Hanel W; Epperla N
J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
[TBL] [Abstract][Full Text] [Related]
7. SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.
Romancik JT; Gerber DG; Zhuang T; Cohen JB
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):557-565. PubMed ID: 35123927
[TBL] [Abstract][Full Text] [Related]
8. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).
Tbakhi B; Reagan PM
Ther Adv Hematol; 2022; 13():20406207221080738. PubMed ID: 35237395
[TBL] [Abstract][Full Text] [Related]
10. [Mantle Cell Lymphoma - Cutting edge Dia-gnostics and Treatment Approaches].
Klener P; Trněný M
Klin Onkol; 2015; 28 Suppl 3():3S80-6. PubMed ID: 26489506
[TBL] [Abstract][Full Text] [Related]
11. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
12. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
13. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
Nabrinsky E; Danilov AV; Koller PB
Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
[TBL] [Abstract][Full Text] [Related]
14. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.
Klener P
Expert Opin Ther Targets; 2020 Oct; 24(10):1029-1045. PubMed ID: 32842810
[TBL] [Abstract][Full Text] [Related]
15. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
[TBL] [Abstract][Full Text] [Related]
16. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
Abramson JS; Ghosh N; Smith SM
Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
18. New Directions for Mantle Cell Lymphoma in 2022.
Kumar A; Eyre TA; Lewis KL; Thompson MC; Cheah CY
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35561299
[TBL] [Abstract][Full Text] [Related]
19. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.
Jain P; Wang M
Am J Hematol; 2019 Jun; 94(6):710-725. PubMed ID: 30963600
[TBL] [Abstract][Full Text] [Related]
20. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
Jain P; Wang ML
Am J Hematol; 2022 May; 97(5):638-656. PubMed ID: 35266562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]